Protox holders okay Warburg investment

Shareholders of Protox Therapeutics (TSX:PRX) at a special meeting overwhelmingly approved a proposed investment of up to $35 million from private equity giant Warburg Pincus. An initial tranche of $10 million is expected to close by Nov. 23.  It would be followed by a further $25 million, subject to the FDA granting a special protocol [...]

Warburg to invest up to $35 million in Protox

Two Warburg Pincus funds have agreed to invest up to $35 million in Protox Therapeutics (TSX:PRX), consisting of an initial tranche of $10 million and an additional tranche of $25 million, resulting in the funds having majority stake in Protox. “Warburg Pincus’ impressive track record of building substantial shareholder value, providing access to growth capital, [...]

Protox lands licensing deal in Japan

Protox Therapeutics (TSX:PRX) has signed a potential $75 million (U.S.) licence agreement with Kissei Pharmaceutical to develop and commercialize Protox’s PRX302 drug in Japan for the treatment of enlarged prostate, prostate cancer and other diseases of the prostate. Under the accord, Protox will receive an upfront payment of $3 million and is eligible to receive [...]

Protox trims size of private placement

Protox Therapeutics (TSX:PRX) has reduced the size of its planned private placement to about $6.5 million from $8 million through the sale of units priced at 45 cents each instead of 55 cents. Each unit consists of one common share of Protox and one-half of a warrant.  Each whole warrant will entitle the holder to [...]